Mark K. Wedel
Keine laufenden Positionen mehr
Profil
Mark K.
Wedel held several positions in the medical field, including Director of Medical Affairs & Pulmonary Therapeutics at the US Department of Justice, Medical Director at Scripps Clinic & Research Foundation, Chief Medical Officer & Senior VP-Development at Ionis Pharmaceuticals, and Chief Medical Officer & Vice President at Roche Innovation Center.
Copenhagen A.
He also served as Chief Medical Officer & Senior VP-Clinical Affairs at AtheroNova, Inc. Dr. Wedel received his undergraduate degree from Valparaiso University, his graduate degree from Thomas Jefferson School of Law, and his doctorate from The Johns Hopkins University School of Medicine.
Ehemalige bekannte Positionen von Mark K. Wedel
| Unternehmen | Position | Ende |
|---|---|---|
| ATHERONOVA INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2015 |
| IONIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.08.2008 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Scripps Clinic & Research Foundation | Technik-/Wissenschafts-/F&E-Leiter | - |
| US Department of Justice | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark K. Wedel
| Valparaiso University | Undergraduate Degree |
| Thomas Jefferson School of Law | Graduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| US Department of Justice | Government |
| Scripps Clinic & Research Foundation | |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
AtheroNova, Inc.
 AtheroNova, Inc. Pharmaceuticals: MajorHealth Technology AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA. | Health Technology |
